tiprankstipranks
Rallybio Strengthens Ties with J&J in FNAIT Treatment Push
Company Announcements

Rallybio Strengthens Ties with J&J in FNAIT Treatment Push

Don't Miss Our Christmas Offers:

Rallybio (RLYB) has provided an update.

Rallybio Corporation has entered into a significant collaboration with Johnson & Johnson to develop treatments for FNAIT, a condition affecting pregnant individuals and newborns. The partnership includes data sharing from Rallybio’s studies and an initial $0.5 million payment from J&J, with potential for $3.7 million more based on milestones. Additionally, Rallybio sold over 3.6 million shares to J&J for $6.6 million and agreed to a 180-day lock-up period on stock sales, underscoring a deepening financial and research relationship between the two companies.

For detailed information about RLYB stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyRallybio price target lowered to $7 from $8 at JMP Securities
TheFlyRallybio to begin RLYB116 confirmatory clinical PK/PD study in Q2
TheFlyRallybio publishes RLYB212 data
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App